Arbutus Biopharma Corporation (ABUS) financial statements (2020 and earlier)
Company profile
| Business Address |
100-8900 GLENLYON PARKWAY BURNABY, BC V5J 5J8 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments, including: | 91 | 125 | 126 | 131 | 181 | 0 | 69 | ||
| Cash and cash equivalents | 32 | 37 | 54 | 23 | 167 | 72 | 69 | ||
| Short-term investments | 59 | 88 | 72 | 107 | 15 | 40 | |||
| Other undisclosed cash, cash equivalents, and short-term investments | (112) | ||||||||
| Receivables | 1 | 2 | 1 | 1 | 1 | 3 | 0 | ||
| Deferred costs | 0 | ||||||||
| Income taxes receivable | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 0 | ||
| Other undisclosed current assets | 2 | 3 | 2 | 1 | 1 | 114 | 1 | ||
| Total current assets: | 94 | 129 | 129 | 133 | 184 | 116 | 70 | ||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 9 | 10 | 12 | 7 | 3 | 2 | 1 | ||
| Long-term investments and receivables | 22 | 10 | |||||||
| Long-term investments | 22 | 10 | |||||||
| Intangible assets, net (including goodwill) | 66 | 83 | 124 | 515 | ✕ | ||||
| Goodwill | 22 | 24 | 24 | 163 | |||||
| Intangible assets, net (excluding goodwill) | 44 | 59 | 99 | 353 | |||||
| Restricted cash and investments | 13 | 13 | |||||||
| Other noncurrent assets | 0 | ||||||||
| Other undisclosed noncurrent assets | 3 | ||||||||
| Total noncurrent assets: | 12 | 99 | 108 | 143 | 528 | 2 | 1 | ||
| TOTAL ASSETS: | 106 | 228 | 237 | 276 | 712 | 118 | 72 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 7 | 9 | 11 | 10 | 9 | 9 | 4 | ||
| Accounts payable | 2 | 3 | 2 | 3 | 3 | ||||
| Accrued liabilities | 1 | 1 | 1 | 1 | 2 | ||||
| Other undisclosed accounts payable and accrued liabilities | 4 | 5 | 8 | 5 | 5 | 9 | 4 | ||
| Restructuring reserve | 0 | 1 | ✕ | ||||||
| Deferred revenue and credits | ✕ | ✕ | 3 | 0 | 1 | 6 | 3 | ||
| Other undisclosed current liabilities | 1 | 0 | 1 | 1 | 1 | 5 | 5 | ||
| Total current liabilities: | 8 | 11 | 15 | 11 | 11 | 20 | 13 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 12 | 12 | |||||||
| Long-term debt, excluding current maturities | 12 | 12 | |||||||
| Liabilities, other than long-term debt | 3 | 4 | 28 | 50 | 154 | 10 | (0) | ||
| Deferred revenue and credits | ✕ | ✕ | 1 | 0 | 10 | (0) | |||
| Deferred rent credit | 1 | ✕ | ✕ | ✕ | ✕ | ✕ | |||
| Deferred tax liabilities, net | ✕ | 17 | 41 | 146 | |||||
| Business combination, contingent consideration, liability | 3 | 3 | 10 | 9 | 7 | ✕ | |||
| Other undisclosed noncurrent liabilities | 22 | 13 | 0 | ||||||
| Total noncurrent liabilities: | 25 | 16 | 40 | 62 | 154 | 10 | |||
| Total liabilities: | 33 | 28 | 55 | 73 | 165 | 30 | 13 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent, including: | 73 | 200 | 182 | 203 | 548 | 88 | 59 | ||
| Preferred stock | 49 | ||||||||
| Common stock | 899 | 879 | 876 | 867 | 834 | 290 | 217 | ||
| Additional paid in capital | 55 | 48 | 43 | 37 | 30 | 26 | 25 | ||
| Accumulated other comprehensive loss | (48) | (48) | (48) | (50) | (50) | (22) | (16) | ||
| Accumulated deficit | (970) | (805) | (738) | (651) | (267) | (206) | (167) | ||
| Warrants and rights outstanding | 5 | 5 | |||||||
| Other undisclosed stockholders' equity attributable to parent | 137 | 126 | 1 | (5) | (5) | ||||
| Total stockholders' equity: | 73 | 200 | 182 | 203 | 548 | 88 | 59 | ||
| TOTAL LIABILITIES AND EQUITY: | 106 | 228 | 237 | 276 | 712 | 118 | 72 | ||
Income statement (P&L) ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue, net | ✕ | ✕ | 11 | 1 | 25 | 15 | 16 | |
| Gross profit: | 6 | 6 | 11 | 1 | 25 | 15 | 15 | |
| Operating expenses | (150) | (96) | (122) | (493) | (127) | (48) | (28) | |
| Operating loss: | (144) | (90) | (111) | (492) | (102) | (33) | (12) | |
| Nonoperating income (expense) | (22) | 28 | 2 | 2 | 25 | 5 | 2 | |
| Investment income, nonoperating | 2 | 28 | 2 | 1 | 1 | 1 | 1 | |
| Foreign currency transaction gain (loss), before tax | 0 | (1) | 2 | 1 | 22 | 4 | 1 | |
| Interest and debt expense | (2) | (0) | (0) | |||||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 0 | 0 | ||||||
| Loss from continuing operations before equity method investments, income taxes: | (168) | (61) | (109) | (489) | (77) | (28) | (11) | |
| Other undisclosed income from continuing operations before income taxes | 2 | |||||||
| Loss from continuing operations before income taxes: | (166) | (61) | (109) | (489) | (77) | (28) | (11) | |
| Income tax benefit | 13 | 4 | 24 | 105 | 16 | |||
| Net loss: | (154) | (57) | (84) | (384) | (61) | (28) | (11) | |
| Other undisclosed net loss attributable to parent | (11) | (4) | ||||||
| Net loss attributable to parent: | (154) | (57) | (84) | (384) | (61) | (39) | (14) | |
| Preferred stock dividends and other adjustments | (11) | (10) | (1) | |||||
| Net loss available to common stockholders, diluted: | (165) | (67) | (85) | (384) | (61) | (39) | (14) | |
Comprehensive Income ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (154) | (57) | (84) | (384) | (61) | (28) | (11) | |
| Other comprehensive income (loss) | (0) | 0 | ||||||
| Comprehensive loss: | (154) | (57) | (84) | (384) | (61) | (28) | (11) | |
| Other undisclosed comprehensive loss, net of tax, attributable to parent | (27) | (17) | (7) | |||||
| Comprehensive loss, net of tax, attributable to parent: | (154) | (57) | (84) | (384) | (89) | (45) | (17) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.